 |
|
Infections Complicating Mycosis Fungoides and Sézary Syndrome
Peter I. Axelrod, MD;
Bennett Lorber, MD;
Eric C. Vonderheid, MD
JAMA. 1992;267(10):1354-1358.
Abstract
| |
Objective.
—To determine, in patients with mycosis fungoides and Sézary syndrome, the incidence of infections, the importance of nosocomial infections, and the epidemiologic factors associated with cutaneous and visceral infections.
Design and Setting.
—Retrospective inception cohort study at a university medical center referral clinic.
Patients.
—Three hundred fifty-six patients with mycosis fungoides or Sézary syndrome.
Main Outcome Measures.
—Incidence rates for specific infections, and multivariate risk ratios for demographic and clinical factors associated with infection.
Results.
—Cutaneous bacterial infection was most common (17.0 infections per 100 patient-years), followed by cutaneous herpes simplex virus and herpes zoster virus infection (3.8 infections per 100 patient-years), bacteremia (2.1 infections per 100 patient-years), bacterial pneumonia (1.7 infections per 100 patient-years), and urinary tract infection (1.4 infections per 100 patient-years). Twenty-seven percent of herpesvirus infections disseminated on the skin but none disseminated to internal organs. Pneumonia or bacteremia was present in 88% of patients who died of infection. Only three patients had invasive fungal or protozoal infection. Nosocomial infections accounted for 19% of cutaneous bacterial infections, 59% of bacteremias, 62% of pneumonias, and 88% of infections leading to death. By logistic and Cox regression, the presence of extracutaneous involvement with lymphoma was the most important independent risk factor for recurrent bacterial skin infection (risk ratio [RR], 12; 95% confidence interval [Cl], 1.2 to 120), disseminated herpesvirus infection (RR, 28; 95% Cl, 2.7 to 290), bloodstream infection (RR, 5.5; 95% Cl, 1.7 to 18), and death from infection (RR, 15; 95% Cl, 3.6 to 64).
Conclusions.
—Community-acquired bacterial skin infections are a common cause of morbidity in patients with mycosis fungoides and Sézary syndrome but are usually treated without hospital admission. Bacteremia and pneumonia, which are usually nosocomial, are the major infectious causes of death. Advanced disease stage, independent of corticosteroids and other therapies, is the most important risk factor for both cutaneous and systemic infections.
(JAMA. 1992;267:1354-1358)
Author Affiliations
From the Section of Infectious Diseases, Department of Medicine (Drs Axelrod and Lorber), and the Department of Dermatology (Dr Vonderheid), Temple University School of Medicine, Philadelphia, Pa. Dr Vonderheid is now with the Department of Dermatology, Hahnemann University Health Sciences Center, Philadelphia.
Footnotes
Reprint requests to Section of Infectious Diseases, Temple University Hospital, 3401 N Broad St, Philadelphia, PA 19140 (Dr Axelrod).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
Piekarz et al.
JCO 2009;27:5410-5417.
ABSTRACT
| FULL TEXT
Immune Function Abnormalities in Peripheral Blood Mononuclear Cell Cytokine Expression Differentiates Stages of Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Chong et al.
Clin. Cancer Res. 2008;14:646-653.
ABSTRACT
| FULL TEXT
Down-Modulation of CXCR3 Surface Expression and Function in CD8+ T Cells from Cutaneous T Cell Lymphoma Patients
Winter et al.
J. Immunol. 2007;179:4272-4282.
ABSTRACT
| FULL TEXT
Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma
Kim et al.
Blood 2007;109:4655-4662.
ABSTRACT
| FULL TEXT
Nonmalignant T cells stimulate growth of T-cell lymphoma cells in the presence of bacterial toxins
Woetmann et al.
Blood 2007;109:3325-3332.
ABSTRACT
| FULL TEXT
Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells
Berger et al.
Blood 2005;105:1640-1647.
ABSTRACT
| FULL TEXT
Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma
Yawalkar et al.
Blood 2003;102:4059-4066.
ABSTRACT
| FULL TEXT
Bexarotene Is Effective and Safe for Treatment of Refractory Advanced-Stage Cutaneous T-Cell Lymphoma: Multinational Phase II-III Trial Results
Duvic et al.
JCO 2001;19:2456-2471.
ABSTRACT
| FULL TEXT
Phase 2 and 3 Clinical Trial of Oral Bexarotene (Targretin Capsules) for the Treatment of Refractory or Persistent Early-Stage Cutaneous T-Cell Lymphoma
Duvic et al.
Arch Dermatol 2001;137:581-593.
ABSTRACT
| FULL TEXT
Profound Deficiency in Normal Circulating T Cells in Erythrodermic Cutaneous T-Cell Lymphoma
Heald et al.
Arch Dermatol 1994;130:198-203.
ABSTRACT
|
